Urotoday International Journal

Home > Current issue

UIJ - Urinary Incontinence, Overactive Bladder, and Enuresis in the Spanish Population: An Epidemiologic, Multicenter, and National Study

Eduardo Martínez-Agulló1, Luis Gómez-Pérez2, Miguel Ramirez-Backhaus1, Pablo Rebollo3, Maite Pérez4, José Chaves5, The EPICC Cooperative Study Group

1 Servicio de Urologia, Hospital Universitario La Fe. Valencia ESP.
2 Servicio de Urología, Hospital Universitario de San Juan. Alicante ESP.
3 BAP Health Outcomes Research. SL Oviedo ESP.
4 Medical Department, Almirall Pharmaceuticals SA. Barcelona ESP.
5 Medical Unit, Pfizer Spain. Madrid ESP.

Date Received July 16, 2011
Accepted on September 02, 2011
Original Publication Date November 23, 2011
E-mail

 

ABSTRACT

 

Introduction: Despite the growing interest on urinary incontinence (UI), nocturnal enuresis (NE), and overactive bladder (OAB), in Spain, there are no epidemiologic studies on the prevalence of these health problems in the different affected groups of the general population. The objective of the present study was to observe the prevalence of the signs and symptoms of UI, OAB, and NE in specific groups of the general population.
Methods: This is an epidemiologic, observational, multicenter, and national study. Data were collected by means of personal interviews in 5 representative areas from Spain and in 4 groups of the population: 1) workingwomen (25 to 64 years old), 2) workingmen (50 to 64 years old), 3) children attending primary school (6 to 11 years old), and 4) elderly, institutionalized subjects (over 65 years old) with no mental impairment. The Interview included 2 parts: 1) sociodemographic variables and clinical history, and 2) data about OAB and UI symptoms. The interview addressing children included sociodemographic variables and questions about liquid intake and urine control.
Results: The percentage of interview answers in the different groups varied between 79.7% and 98%. The prevalence of isolated OAB and UI in workingwomen (N = 3090) was 2.69% and 4.01%, respectively; in men (N = 1071) prevalence was 3.55% and 0.56%; in the elderly (N = 996) prevalence was 9.14% and 15.16%. In total, 9.94% (95% confidence interval [CI] = 8.9 to 11.04) of the women under study suffer 1 or both health problems. This percentage was 5.14% (95% CI = 3.89 to 6.63) in men and 53.71% (95% CI = 50.56 to 56.85) in the elderly. The prevalence of nocturnal enuresis in children (N = 1279) was 7.82% (95% CI = 6.62 to 9.17).
Conclusions: The prevalence of OAB and/or UI in Spain is nearly 10% of women between 25 and 64 years old, is around 5% in men between 50 and 64 years old, and it is over 50% in persons over 65 years. The prevalence of nocturnal enuresis in children between 6 and 11 years is around 8%.
KEYWORDS: Epidemiology; Overactive bladder; Urinary incontinence; General population; Prevalence

CORRESPONDENCE: Pablo Rebollo, MD, BAP Health Outcomes Research, Azcárraga, 33010 Oviedo, Spain (pablo@baphealth.com).

CITATION: Urotoday Int J. 2011 Dec;4(6):art78. http://dx.doi.org/10.3834/uij.1944-5784.2011.12.11

Login to view this Article.Login Here

Abstract | Download Citation | Full Text

case diagnosis

Participate Now
CME - Frequently Asked Questions in Improving Detection and Initial Treatment of Bladder Cancer


Presented by the Warren Alpert Medical School of Brown University, Office of Continuing Medical Education.

Target Audience

This activity is designed for urologists and other healthcare professionals interested in or involved with the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be able to:

  1. Discuss the epidemiology of bladder cancer including prevalence, mortality, and risk factors
  2. Describe the economic impact of bladder cancer and how improved techniques for initial detection and at the time of transurethral resection of bladder tumor (TURBT) may decrease the economic burden
  3. Compare and contrast new urine biomarkers when compared to urine cytology
  4. Discuss the role of photodynamic diagnosis using hexaminolevulinate-guided fluorescence cystoscopy in detecting carcinoma in situ and residual disease at the time of TURBT compared to traditional white-light cystoscopy (WLC)
  5. Optimize use of intravesical therapy after TURBT to prevent recurrence of bladder...
    Take CME
CME - Frequently Asked Questions in the Management of Castrate-Resistant Prostate Cancer (CRPC)

An Expert Panel Interview

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify patients with castrate-resistant prostate cancer (CRPC)

  • Review current and future modalities available for the treatment of CRPC.

  • Discuss therapeutic strategies that may mitigate skeletal adverse events associated with metastatic prostate cancer and its treatment.

  • Program Release: April 1, 2011

  • Program Expiration: April 30, 2012

  • Estimated time to complete: 60 minutes

  • There are no prerequisites for participation.

  • 1 AMA PRA Category 1 Credit™

  • Educational grant provided by Amgen Inc and Dendreon Corporation.

Take CME
mobile news
Visit our mobile news channel today and get the latest Urological reviews, conference coverage, surgical techniques, clinical updates and more!